Essex Bio-Technology Limited

Research Essex Bio-Technology Limited (1061.HK) on Bullrun: market cap HKD 1.18B, P/E 4.4, dividend yield 5.7%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is HKD 1.18B; P/E is 4.4; dividend yield is 5.7%.

Peer valuation comparison

Latest P/E is 4.44x versus a Healthcare sector median of 21.69x (79.5% below).

Latest dividend yield is 5.66% versus a Healthcare sector median of 2.41% (134.9% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025HKD 1.81BHKD 318.09MHKD 131.71M89.2%0.56HKD 782.73MHKD 346.90MHKD 2.41B
FY2024HKD 1.67BHKD 307.22MHKD 249.00M89.8%0.53HKD 557.17MHKD 187.04MHKD 2.12B
FY2023HKD 1.74BHKD 275.26MHKD 211.16M89.9%0.47HKD 509.85MHKD 294.02MHKD 1.92B
FY2022HKD 1.32BHKD 225.41MHKD 99.87M90.3%0.38HKD 543.49MHKD 489.73MHKD 1.73B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-18HKD 1.18B4.45.8%0.12

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.12 HKD, yield 5.7%.

YearDividends/share
FY20250.13 HKD
FY20240.11 HKD
FY20230.07 HKD
FY20220.1 HKD
FY20210.09 HKD

About Essex Bio-Technology Limited

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally. It operates through Ophthalmology, Surgical, and Healthcare and Partner Services segments. The company researches and develops therapeutic fibroblast growth factor products to treat cellular proliferation, differentiation, and migration. It offers Beifushu series, such as Beifushu eye drops, eye gel, and unit-dose eye drops to treat ocular wounds;

Related stock research

China stocks China Healthcare stocks A-Z stock index

Other Healthcare stocks

Shandong Dong-Ee Jiao Co Ltd (000423.SZ) Livzon Pharmaceutical Group Inc (000513.SZ) Yunnan Baiyao Group Co., Ltd. (000538.SZ) Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ) Chang Chun High and New Technology Industry (Group) Inc. (000661.SZ) Apeloa Pharmaceutical Co., Ltd. (000739.SZ) Huadong Medicine Co Ltd (000963.SZ) China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999.SZ) Zhejiang NHU Co Ltd (002001.SZ) Jiangsu Nhwa Pharmaceutical Co Ltd (002262.SZ) Shijiazhuang Yiling Pharmaceutical Co Ltd (002603.SZ) Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ)

Frequently asked questions

What is Essex Bio-Technology Limited's market cap?

Essex Bio-Technology Limited's market capitalization is HKD 1.18B.

What is Essex Bio-Technology Limited's P/E ratio?

Essex Bio-Technology Limited's price-to-earnings (P/E) ratio is 4.4.

Does Essex Bio-Technology Limited pay a dividend?

Essex Bio-Technology Limited has a dividend yield of 5.7%.

What does Essex Bio-Technology Limited do?

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally. It operates through Ophthalmology, Surgical, and Healthcare and Partner Services segments. The company researches and develops therapeutic fibroblast growth factor products to treat cellular proliferation, differentiation, and migration.